First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis

ObjectivePrognosis of patients with irresectable cholangiocarcinoma is still poor. The ABC-02 trial established the current first line (1L) standard systemic chemotherapy (CT) with gemcitabine/platinum derivate for advanced cholangiocarcinoma. However, the majority of patients needed therapy adaptio...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Christian Möhring, Jan Feder, Raphael U. Mohr, Farsaneh Sadeghlar, Alexandra Bartels, Robert Mahn, Taotao Zhou, Milka Marinova, Georg Feldmann, Peter Brossart, Martin von Websky, Hanno Matthaei, Steffen Manekeller, Tim Glowka, Jörg C. Kalff, Tobias J. Weismüller, Christian P. Strassburg, Maria A. Gonzalez-Carmona
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	bile duct carcinoma cholangiocellular carcinoma first line palliative chemotherapy second line palliative chemotherapy retrospective analysis gemcitabine/cisplatin Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/3a0b0c8729054bd493c1b136c9000bca
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis

Ejemplares similares